Contract ImpactThe DHA extension removes the greatest near-term catalyst for upside, which may keep shares range bound until further clarity emerges around topline growth.
Revenue OutlookThe reduction in the FY25 topline outlook is caused by the DHA extension, as the previous forecast had assumed expansion revenues in the second half of FY25.
Topline GuidanceA negative topline guidance revision stems from the extension of the DHA contract for 2026, which will exclude automated care and behavioral health components due to budget constraints.